clinical trial · NCT06117774
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Amgen·phase3·recruiting·n = 400
Limited Stage Small Cell Lung CancerSmall Cell Lung CancerTarlatamabPlacebo
brief summary
The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on blinded independent central review (BCIR) per response evaluation criteria in solid tumors v1.1 (RECIST 1.1) and on prolonging overall survival (OS).
started
Feb 20, 2024
primary completion
May 29, 2030
completion
May 29, 2030
last updated
Apr 15, 2026
official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol